Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ASPCFNASDAQ:CBLINASDAQ:FWPNASDAQ:INDPOTCMKTS:OTLC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/ACBLICleveland BioLabs$0.00$3.19$1.62▼$10.97$9K0.7271,922 shs1,030 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AINDPIndaptus Therapeutics$2.24-10.0%$1.91$1.56▼$4.08$19.13M1.2683,937 shs55,513 shsOTLCOncotelic Therapeutics$0.04$0.04$0.01▼$0.06$14.35M0.1270,782 shs12,017 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CBLICleveland BioLabs0.00%0.00%0.00%0.00%-95.71%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%INDPIndaptus Therapeutics-10.11%+7.33%+29.69%+43.10%+41.48%OTLCOncotelic Therapeutics-8.86%-3.23%-4.51%+5.57%-26.38%Urgent: Protect Your Investments from a Chinese Invasion (Ad)An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AINDPIndaptus Therapeutics2.0831 of 5 stars3.53.00.00.02.91.70.0OTLCOncotelic TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPCFAcerus PharmaceuticalsN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AINDPIndaptus Therapeutics3.00Buy$12.00435.71% UpsideOTLCOncotelic TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07CBLICleveland BioLabs$260K0.04N/AN/A$0.87 per share0.00FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/A$0.05 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/ACBLICleveland BioLabs-$2.40MN/A0.00∞N/AN/A-32.84%-31.29%N/AFWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AINDPIndaptus Therapeutics-$15.42M-$1.84N/A∞N/AN/A-91.78%-80.42%5/9/2024 (Estimated)OTLCOncotelic Therapeutics$5.09MN/A0.00∞N/AN/A-83.41%-38.88%4/15/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASPCFAcerus PharmaceuticalsN/A0.670.34CBLICleveland BioLabsN/A45.9345.93FWPForward Pharma A/SN/A18.43N/AINDPIndaptus TherapeuticsN/A5.055.05OTLCOncotelic Therapeutics0.070.020.02OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPCFAcerus PharmaceuticalsN/ACBLICleveland BioLabs5.09%FWPForward Pharma A/S12.57%INDPIndaptus Therapeutics7.06%OTLCOncotelic TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipASPCFAcerus PharmaceuticalsN/ACBLICleveland BioLabs1.03%FWPForward Pharma A/S71.47%INDPIndaptus Therapeutics27.10%OTLCOncotelic Therapeutics39.22%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableCBLICleveland BioLabs415.48 millionN/ANot OptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableINDPIndaptus Therapeutics78.54 million6.23 millionNot OptionableOTLCOncotelic Therapeutics22398.67 million242.31 millionNot OptionableFWP, CBLI, INDP, OTLC, and ASPCF HeadlinesSourceHeadlineLinkage of Cancer and Lupus in Gliomas Patientsfinance.yahoo.com - March 25 at 8:20 AMLinkage of Cancer and Lupus in Gliomas Patientsglobenewswire.com - March 25 at 8:10 AMInvitation to Participate in STOP-PC Clinical Trialglobenewswire.com - March 4 at 8:17 AMOncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning Callsbenzinga.com - February 22 at 11:33 PMOncotelic Therapeutics Strikes Material Definitive Legal Agreementmsn.com - February 3 at 2:28 PMLineage Cell Therapeutics Inc LCTXmorningstar.com - January 23 at 8:50 PMOncotelic Therapeutics Announces Opening of GMP Manufacturing Plantfinance.yahoo.com - December 18 at 8:33 AMOncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Resultsfinanznachrichten.de - November 15 at 3:15 PMOncotelic Therapeutics reports Q3 resultsmsn.com - November 15 at 10:15 AMOncotelic Reports Q3 2023 Compared to Q3 2022 Financial Resultsfinance.yahoo.com - November 15 at 10:15 AMThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Chargebenzinga.com - September 11 at 6:04 PMThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Chargebenzinga.com - September 11 at 6:04 PMOncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023finance.yahoo.com - August 25 at 9:09 AMSapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancerfinance.yahoo.com - August 23 at 9:05 AMOncotelic Participating at 2023 BIO International Conventionfinance.yahoo.com - May 16 at 8:20 AMOncotelic Launches PDAO SEC Chatbottechnews.tmcnet.com - April 24 at 7:46 AMOncotelic Therapeutics reports FY resultsseekingalpha.com - April 20 at 12:52 AMOncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technologyfinance.yahoo.com - April 19 at 9:51 AMHigh Intra-Tumor TGF-ß2 Predicts Poor Survival in Pediatric Cancer of the Brainstemtechnews.tmcnet.com - March 13 at 10:57 AMOTLC Oncotelic Therapeutics, Inc.seekingalpha.com - February 15 at 11:34 PMOncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancerfinance.yahoo.com - February 6 at 8:25 AMOncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancerfinance.yahoo.com - January 25 at 9:28 AMOncotelic Issues Year End Message to Shareholdersfinance.yahoo.com - December 28 at 8:14 AMOncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomasfinance.yahoo.com - November 8 at 7:40 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcerus PharmaceuticalsOTCMKTS:ASPCFAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Cleveland BioLabsNASDAQ:CBLICytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Indaptus TherapeuticsNASDAQ:INDPIndaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Oncotelic TherapeuticsOTCMKTS:OTLCOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.